Phase III study of Efficacy and Safety of SJP-0118 in bacterial blepharitis, dacryocystitis or hordeolum/ acute suppurative chalazion.

Trial Profile

Phase III study of Efficacy and Safety of SJP-0118 in bacterial blepharitis, dacryocystitis or hordeolum/ acute suppurative chalazion.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2016

At a glance

  • Drugs SJP 0118 (Primary)
  • Indications Blepharitis; Chalazion; Dacryocystitis
  • Focus Therapeutic Use
  • Sponsors Senju Pharmaceutical
  • Most Recent Events

    • 28 Jul 2016 Status changed from recruiting to completed.
    • 13 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top